drugset / Trial / NCT05662098
Alternative Dosing And Prevention of Transfusions (ADAPT)
Phase 0
Active not recruiting
100 enrolled
Children's Hospital Medical Center, Cincinnati
Jinja Regional Referral Hospital (JRRH), Sickle Cell Clinic, Jinja, Uganda · collab
NaSingle-groupOpen-labelTreatment
Summary
ADAPT is a prospective cohort study at Jinja Regional Referral Hospital (JRRH) primarily to assess the effect of hydroxyurea on blood transfusion utilization and secondarily to determine the feasibility of PK-guided hydroxyurea dosing.
Timeline
- Start
- 2022-06-16
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Publications
- Power-Hays A, Namazzi R, Dong M, Kazinga C, Kato C, Aliwuya S, McElhinney K, Conroy AL, Lane A, John C, Vinks AA, Latham T, Opoka RO, Ware RE. The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. Br J Clin Pharmacol. 2025 Jun;91(6):1865-1872. doi: 10.1111/bcp.70071.
- Power-Hays A, Namazzi R, Dong M, Kazinga C, Kato C, Aliwuya S, McElhinney K, Conroy AL, Lane A, John C, Vinks AA, Latham T, Opoka RO, Ware RE. The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. Br J Clin Pharmacol. 2025 Apr 13;91(6):1865-72. doi: 10.1002/bcp.70071. Online ahead of print.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxyurea | Other / unclassified | 20 mg/kg | — |